Current standardized therapeutic approach for uveitis in Japan

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Uveitis, an ocular disease, is linked to systemic immune-mediated and infectious conditions.
• Differentiating infectious from non-infectious uveitis is vital for accurate diagnosis and effective treatment.
• Non-infectious uveitis diagnosis can be challenging, necessitating the exclusion of infectious causes.

Purpose of the Study:

• To review the characteristics of typical non-infectious uveitis in Japan.
• To outline current treatment methods for non-infectious uveitis in Japan.
• To highlight the limited availability of immunosuppressive and biologic drugs for uveitis in Japan.

Main Methods:

• Literature review focusing on non-infectious uveitis.
• Analysis of clinical characteristics and treatment strategies.
• Examination of drug availability for uveitis treatment in Japan.

Main Results:

• Non-infectious uveitis shares some symptoms with infectious uveitis, complicating clinical diagnosis.
• Japan has limited treatment options, with Cyclosporin A as the sole approved immunosuppressive drug for uveitis.
• Infliximab and Adalimumab are the only approved biologic agents for uveitis treatment in Japan.

Conclusions:

• Accurate differentiation between infectious and non-infectious uveitis is paramount for appropriate patient management.
• The restricted availability of immunosuppressive and biologic agents in Japan poses challenges for treating non-infectious uveitis.
• Further research and expanded therapeutic options are needed for non-infectious uveitis in the Japanese context.